Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA324290
Max Phase: Preclinical
Molecular Formula: C16H17NO2
Molecular Weight: 255.32
Molecule Type: Small molecule
Associated Items:
ID: ALA324290
Max Phase: Preclinical
Molecular Formula: C16H17NO2
Molecular Weight: 255.32
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1cc(/C=C/c2ccc(N)cc2)cc(OC)c1
Standard InChI: InChI=1S/C16H17NO2/c1-18-15-9-13(10-16(11-15)19-2)4-3-12-5-7-14(17)8-6-12/h3-11H,17H2,1-2H3/b4-3+
Standard InChI Key: LGVZJSLFOMGJOS-ONEGZZNKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 255.32 | Molecular Weight (Monoisotopic): 255.1259 | AlogP: 3.46 | #Rotatable Bonds: 4 |
Polar Surface Area: 44.48 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 3.99 | CX LogP: 3.17 | CX LogD: 3.17 |
Aromatic Rings: 2 | Heavy Atoms: 19 | QED Weighted: 0.67 | Np Likeness Score: 0.09 |
1. Roberti M, Pizzirani D, Simoni D, Rondanin R, Baruchello R, Bonora C, Buscemi F, Grimaudo S, Tolomeo M.. (2003) Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents., 46 (16): [PMID:12877593] [10.1021/jm030785u] |
2. Liu H, Dong A, Gao C, Tan C, Liu H, Zu X, Jiang Y.. (2008) The design, synthesis, and anti-tumor mechanism study of N-phosphoryl amino acid modified resveratrol analogues., 16 (23): [PMID:18952444] [10.1016/j.bmc.2008.10.022] |
3. Sun B, Hoshino J, Jermihov K, Marler L, Pezzuto JM, Mesecar AD, Cushman M.. (2010) Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer., 18 (14): [PMID:20558073] [10.1016/j.bmc.2010.05.042] |
4. Paul S, Mizuno CS, Lee HJ, Zheng X, Chajkowisk S, Rimoldi JM, Conney A, Suh N, Rimando AM.. (2010) In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer., 45 (9): [PMID:20627379] [10.1016/j.ejmech.2010.05.019] |
5. Uzura S, Sekine-Suzuki E, Nakanishi I, Sonoda M, Tanimori S.. (2016) A facile and rapid access to resveratrol derivatives and their radioprotective activity., 26 (16): [PMID:27426305] [10.1016/j.bmcl.2016.07.018] |
Source(1):